Guselkumab Provides Relief For Patients Who Suffer With Psoriasis Overview A 52-week postmarketing surveillance study was launched to assess the safety and effectiveness of guselkumab, a human monoclonal antibody targeting the interleukin-23 subunit p19, in Japanese patients diagnosed with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis in real-world clinical
Tag: psoriatic arthritis
Golimumab Compliance In Long-Term Arthritis Treatment
Golimumab Compliance In Long-Term Arthritis Treatment STUDY BACKGROUND Biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are the cornerstones in treating inflammatory arthritides such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). Tumor necrosis factor-alpha (TNFα) inhibitors, including adalimumab, infliximab and golimumab are the most commonly prescribed
